1 report

  • 03/09/2016: Probiodrug PGLU-ABETA Approaches Being Presented At 14Th Aat Symposium On Advances In Alzheimer Therapy
  • Apr 04, 2016: Probiodrug announces results of chronic toxicology studies with PQ912, its 'first in class' Glutaminyl Cyclase inhibitor for the treatment of Alzheimer's disease

These data clearly support the hypothesis of pGlu-Abeta being synaptotoxic and the effect of Glutaminyl Cyclase (QC)-inhibitors on reversing this pathology.

  • Dementia
  • Pathology
  • Austria
  • United States
  • Probiodrug AG